NASOPHARYNGEAL CANCER

BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021

Retrieved on: 
Friday, December 10, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Nasopharyngeal Cancer, Tislelizumab, the Tislelizumab Clinical Program, BeiGene, NASOPHARYNGEAL CANCER, TISLELIZUMAB, THE TISLELIZUMAB CLINICAL PROGRAM, BEIGENE

A filing based on these results is currently under review in China, where NPC as an endemic disease remains a significant unmet medical need.

Key Points: 
  • A filing based on these results is currently under review in China, where NPC as an endemic disease remains a significant unmet medical need.
  • Safety results in both arms remained similar to known risks and no new safety signals were identified.
  • The safety profile of tislelizumab and chemotherapy combination was manageable, consistent with known risks of each treatment agent.
  • BeiGene has initiated or completed 17 potentially registration-enabling clinical trials in China and globally, including 13 Phase 3 trials and four pivotal Phase 2 trials.